Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providers
Gynecologic Oncology Physician in Rancho Mirage, CA
NPI: 1043250566Primary Practice Location
EISENHOWER MEDICAL CENTER
39000 Bob Hope Dr, Rancho Mirage, CA
Primary Employer
Eisenhower Medical Center
eisenhowerhealth.org
HQ Phone
Get M.D. Mark's Phone Numberphone_androidMobile
Get M.D. Mark's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
CA State Medical License
2015 - 2026
OK State Medical License
2008 - 2016
NM State Medical License
1995 - 1999
IL State Medical License
1985 - 1996
American Board of Obstetrics and Gynecology
Obstetrics & Gynecology
American Board of Obstetrics and Gynecology
Gynecologic Oncology
University of Tennessee Health Science Center College of Medicine - Memphis
uthsc.edu
Medical School
Until 1985
Loyola University Medical Center
Fellowship • Gynecologic Oncology
1993 - 1995
University of Southern California/Los Angeles General Medical Center (USC/LA General)
Residency • Obstetrics and Gynecology
1986 - 1989
McGaw Medical Center of Northwestern University
Residency • Internal Medicine
1985 - 1985
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 93 | 164 |
| 2 | 99215Established patient office or other outpatient, visit typically 40 minutes | 86 | 148 |
| 3 | 99213Established patient office or other outpatient visit, typically 15 minutes | 73 | 92 |
| 4 | 99205New patient office or other outpatient visit, typically 60 minutes | 62 | 62 |
| 5 | 99204New patient office or other outpatient visit, 45-59 minutes | 38 | 38 |
Are antioxidant levels measured immediately postoperatively an indicator of magnitude of injury?
Authors: Morris, D M, Smith, H O, Liu, W, Genesen, M C, Vander Jagt, D H, Glew, R H, Fry, D E
Journal: Am J Surg
Using the fax--concerns about patient confidentiality.
Authors: Sharp, H M, Genesen, L B, Genesen, M
Journal: West J Med
A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer.
Authors: John Brown
Lead Sponsor: National Cancer Institute (NCI)
Collaborators: NRG Oncology, Canadian Cancer Trials Group
Intervention / Treatment: DRUG: Carboplatin, OTHER: Questionnaire Administration, BIOLOGICAL: Pembrolizumab, OTHER: Quality-of-Life Assessment, DRUG: Paclitaxel, OTHER: Placebo Administration, PROCEDURE: Computed Tomography
Lead Sponsor: National Cancer Institute (NCI)
Collaborators: NRG Oncology
Intervention / Treatment: BIOLOGICAL: Bevacizumab, OTHER: Quality-of-Life Assessment, DRUG: Atezolizumab, PROCEDURE: Computed Tomography, DRUG: Pegylated Liposomal Doxorubicin Hydrochloride
